3-allyl-4-chloro-1,2,5-thiadiazole

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 3-allyl-4-chloro-1,2,5-thiadiazole
• 英文别名: 3-chloro-4-allyl-1,2,5-thiadiazole；3-Chloro-4-prop-2-enyl-1,2,5-thiadiazole
• 化学式: C₅H₅ClN₂S
• 分子量: 160.627
• InChiKey: FYLNMWYCJLRBSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  烯丙基三丁基锡 、 3,4-二氯-1,2,5-噻二唑 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 反应 30.0h， 以31%的产率得到3-allyl-4-chloro-1,2,5-thiadiazole
  参考文献：
  名称：

  The Palladium-catalyzed Cross-Coupling Reactions of 3-Chloro-4-halogeno-1,2,5-thiadiazoles

  摘要：

  3,4-Dichloro- and 3-chloro-4-halogeno-1,2,5-thiadiazoles (halogeno-: bromo- and iodo-) are involved in Pd-catalyzed cross-coupling reactions under Stille and Suzuki conditions. As a result, by using the commercially available 3,4-dichloro-1,2,5-thiadiazole as substrate, several 3-alkyl-, 3-alkenyl-, 3-alkynyl-and 3-aryl-4-chloro-1,2,5-thiadiazoles can easily be prepared. However, these reactions through direct desymmetrization of the 3,4-dichloro-1,2,5-thiadiazole always occur with side-reactions resulting from the concurrent decomposition of the heterocyclic ring of the starting material. These problems are resolved by involving, in these Pd-catalyzed cross-coupling reactions, the more reactive and selective 3-bromo-4-chloro- and 3-chloro-4-iodo-1,2,5-thiadiazole. These new dihalogeno-1,2,5-thiadiazoles can easily be prepared, via diazotization reaction followed by halogen substitution, from the 3-amino-4-chloro-1,2,5-thiadiazole.

  DOI：

  10.3987/com-02-9550

文献信息

• Drug Resistance Reversal In Neoplastic Disease
  申请人：Patil Ghanshyam

  公开号：US20080200405A1

  公开（公告）日：2008-08-21

  The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.

  本发明涉及用于阻止或逆转肿瘤性疾病化疗耐药效应的化合物、组合物和方法。具体描述了羟胺的使用。
• HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE
  申请人：Patil Ghanshyam

  公开号：US20080280890A1

  公开（公告）日：2008-11-13

  The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.

  本公开提供了包括式I或II的羟胺化合物、制药组合物以及它们的使用方法。该方法利用羟胺化合物及/或其制药组合物治疗血管生成、肝炎、补体介导的病理、色斑介导的病理、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病，并抑制补体激活。
• Hydroxylamine compounds and methods of their use
  申请人：Colby Pharmaceutical Company

  公开号：EP2620429A1

  公开（公告）日：2013-07-31

  The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.

  本公开提供了包括式 I 或式 II 的羟胺化合物、药物组合物及其使用方法。这些方法利用羟胺化合物和/或其药物组合物治疗血管生成、肝炎、补体介导的病变、褐斑介导的病变、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病以及抑制补体活化。
• DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE
  申请人：Othera Holding, Inc.

  公开号：EP2120942A2

  公开（公告）日：2009-11-25
• US6620940B1
  申请人：——

  公开号：US6620940B1

  公开（公告）日：2003-09-16